A Phase IIa Randomized, Double-Blinded Clinical Trial of Naproxen or Aspirin for Cancer Immune Interception in Lynch Syndrome

NCT05411718 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

T Cells
Colorectal Cancer
Lynch Syndrome

Interventions

DRUG: Naproxen
DRUG: Aspirin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]